Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Kidney Cancer
- Surgical Oncology
- General Oncology
- Endoscopy Methods
- Melanoma/Skin Cancer
- Pancreatic Cancer
- Urological Cancers
- Chemoprevention
Abstract
Citation: Clin Oncol. 2020;5(1):1753.DOI: 10.25107/2474-1663.1753
Prognosis and Outcome of Patients with Pulmonary Carcinoid Tumors: Experience at the MENA Region
Firas Kreidieh, Imad Bou Akl, Haidar El Darsa, Rola El Sayed, Jessica Khoury, Ibrahim A Alameh, Juliett Berro, Maroun Bou Zerdan, Clara El Nakib, Ali Shamseddine, Arafat Tfayli, Pierre Sfeir, Jamil Borgi and Hazem I Assi
Department of Internal Medicine, American University of Beirut Medical Center, Lebanon
Department of Surgery, American University of Beirut Medical Center, Lebanon
*Correspondance to: Hazem I Assi
PDF Full Text Research Article | Open Access
Abstract:
Introduction: Carcinoid tumors are a subset of neuroendocrine tumors, with Pulmonary Carcinoids (PC) being the second most involved type. PC are classified into Typical (TC) and Atypical (AC) subtypes. They have a low incidence, with relatively high survival rates. In this study, we report the characteristics, prognosis, and outcomes of patients with PC at the American University of Beirut Medical Center (AUBMC) to better understand these tumors and their prognostic markers. To our knowledge, this is the first study of its kind in the Middle East and North African (MENA) region.
Materials and Methods: This is a retrospective chart-review based study at our tertiary referral center, with 36 consecutive patients with PC from 1993 till 2017. Information collected encompassed demographics, tumor characteristics, recurrence, and survival. All patients were called as the last follow-up on 24/1/2019.
Results: 39% of patients were asymptomatic at diagnosis. Most patients had early-stage disease. 80% of patients had typical PC, and 20% had atypical PC with both subtypes having good outcomes, except for a higher progression rate among atypical subtype (60%). The median time to disease progression or recurrence was 6 years. Only 2 patients passed away. Immunohistochemical (IHC) markers were not assessed in all patients and those tested showed high sensitivity for chromogranin A (82%) and synaptophysin (100%).
Conclusion: Our study gives insight about patients with PC in Lebanon and the MENA region with a low incidence of disease. Most patients are surgically treated and have a good survival rate. IHC markers should be better implemented. Larger studies are needed to elaborate and verify our results.
Keywords:
Carcinoid tumors; Lung; Neuroendocrine tumor; Chemotherapy; Surgery; Radia
Cite the Article:
Kreidieh F, Akl IB, El Darsa H, El Sayed R, Khoury J, Alameh IA, et al. Prognosis and Outcome of Patients with Pulmonary Carcinoid Tumors: Experience at the MENA Region. Clin Oncol. 2020;5:1753..